Introduction {#section1-2398212818817494}
============

The potent actions of adenine compounds were first described by Drury and Szent-Györgyi in [@bibr56-2398212818817494]. Years later, adenosine 5′-triphosphate (ATP) was proposed as the transmitter responsible for non-adrenergic, non-cholinergic transmission in the gut and bladder, and the term 'purinergic' was introduced by Burnstock in [@bibr19-2398212818817494]. Early resistance to this concept was understandable since ATP was recognised first for its intracellular roles in many biochemical processes and the intuitive feeling was that such a ubiquitous and simple compound was unlikely to be utilised as an extracellular messenger. However, enzymes involved in the breakdown of extracellular ATP had already been described by the mid-1990s (see [@bibr127-2398212818817494]).

The concept of purinergic neurotransmission and the potent actions of extracellular ATP on many different cell types implied that there were purinergic membrane receptors. Purinergic receptors were described first in 1976 ([@bibr20-2398212818817494]). Two years later, a basis for distinguishing two families of purinoceptors was proposed, identifying P1 and P2 receptors (for adenosine and ATP/adenosine 5′-diphosphate (ADP), respectively; [@bibr21-2398212818817494]). Soon after, two subtypes of the P1 (adenosine) receptor were recognised ([@bibr82-2398212818817494]; [@bibr117-2398212818817494]). In 1985, a pharmacological basis for distinguishing two subtypes of P2 receptor (P2X and P2Y) was proposed ([@bibr38-2398212818817494]). In the early 1990s, P1 (adenosine) receptors were cloned and characterised, and four subtypes were recognised (see [@bibr59-2398212818817494]). In 1993, the first G protein-coupled P2Y receptors were cloned ([@bibr83-2398212818817494]; [@bibr122-2398212818817494]) and a year later two P2X ligand-gated ion channel receptors ([@bibr15-2398212818817494]; [@bibr116-2398212818817494]). In 1994, it was proposed, on the basis of molecular structure and transduction mechanisms, that purinoceptors should belong to these two major families ([@bibr1-2398212818817494]). Currently, seven P2X receptor subtypes and eight P2Y receptor subtypes are recognised, including receptors that are sensitive to pyrimidines as well as purines ([@bibr4-2398212818817494]; [@bibr88-2398212818817494]; [@bibr91-2398212818817494]).

Purinergic signalling appears to be a primitive evolutionary system (see [@bibr119-2398212818817494]). Many non-neuronal as well as neuronal mechanisms, including immune responses, exocrine and endocrine secretion, inflammation, pain, platelet aggregation and endothelial-mediated vasodilatation, involve purinergic signalling in mammals ([@bibr27-2398212818817494]; [@bibr39-2398212818817494]). Cell proliferation, differentiation and death that occur in development and regeneration are also mediated by purinergic receptors ([@bibr2-2398212818817494]; [@bibr41-2398212818817494]). Reviews describe the history of the development of purinergic signalling and discuss future developments ([@bibr33-2398212818817494], [@bibr35-2398212818817494]).

P1 receptors {#section2-2398212818817494}
============

Complementary DNAs encoding for two P1 receptor subtypes (A~1~ and A~2~) were isolated in 1989 ([@bibr81-2398212818817494]). Soon after, the A~3~ subtype was identified ([@bibr129-2398212818817494]). Four different P1 receptor subtypes, A~1~, A~2A~, A~2B~ and A~3~, were cloned and characterised in the early 1990s (see [@bibr59-2398212818817494]). Polymorphisms have been observed in the A~1~ and the A~2A~ receptors ([@bibr73-2398212818817494]). P1 receptors couple to adenylate cyclase; A~1~ and A~3~ are negatively coupled to adenylate cyclase, while A~2A~ and A~2B~ are positively coupled to adenylate cyclase ([@bibr92-2398212818817494]). P1 subtype-selective agonists and antagonists have been identified (see [Table 1](#table1-2398212818817494){ref-type="table"}). P1 receptor subtypes mediate diverse physiological effects, including modulation of cardiovascular, immune and central nervous system (CNS) activities ([@bibr77-2398212818817494]; [@bibr109-2398212818817494]).

###### 

Characteristics of purine-mediated receptors.

![](10.1177_2398212818817494-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Receptor   Main distribution   Agonists                                                                                      Antagonists                                                                                                                         Transduction mechanisms                                                                                                                                                                                                
  ---------- ------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  P1 (Ado)   A~1~                Brain, spinal cord, testis, heart, autonomic nerve terminals                                  CCPA \> R-PIA = S-ENBA; CVT-510; GR79236\                                                                                           DPCPX, N-0840, MRS1754, WRC-0571, PSB36, SLV320, CGS 16943, PQ-69                                                                                                                                                      G~i~/G~o~ ↓cAMP
                                                                                                                               2′-MeCCPA, SDZ WAG 994, INO-8875, MRS 5474                                                                                                                                                                                                                                                                                                                 

             A~2A~               Brain, heart, lungs, spleen                                                                   HENECA \> CGS 21680 = CVT-3146; ATL-146e; Regadenoson                                                                               KF17837, SCH58261, ZM241385, KW 6002                                                                                                                                                                                   G~S~ ↑cAMP

             A~2B~               Large intestine, bladder                                                                      Bay60-6583, NECA                                                                                                                    PSB603, MRE-2029-F20, MRS1754, PSB0788 MRS1706, PSB1115, Alloxazine, GS-6201                                                                                                                                           G~S~ ↑cAMP

             A~3~                Lung, liver, brain, testis, heart                                                             IB-MECA \> MRS5698 \> MRS5168 \> 2-Cl-IB-MECA; DBXRM; VT160; HEMADO                                                                 MRS1220, L-268605, MRS1191, MRS1523(rat), VUF8504, VUF5574, MRS1334(human), PSB10                                                                                                                                      G~i~/G~o~, G~q~/G~11~, ↓cAMP, PLC-β activation

  P2X        P2X1                Smooth muscle, platelets, cerebellum, dorsal horn spinal neurons                              BzATP \> ATP = 2-MeSATP ⩾ α,β-meATP = L-β,γ-meATP (rapid desensitisation); PAPET-ATP                                                NF864 \> NF449 \> IP~5~I ⩾ TNP-ATP \> RO 0437626 \> NF279, NF023, RO1, MRS2159                                                                                                                                         Intrinsic cation channel (Ca^2+^ and Na^+^)

             P2X2                Smooth muscle, CNS, retina, chromaffin cells, autonomic and sensory ganglia, pancreas         ATP ⩾ ATPγS⩾2-MeSATP \>\> α,β-meATP (pH + zinc sensitive); β,γ-CF~2~ATP                                                             PSB-1011 \> RB2, isoPPADS \> PPADS \> Suramin, NF770, NF778, Aminoglycoside                                                                                                                                            Intrinsic ion channel (particularly Ca^2+^)

             P2X3                Sensory neurones, NTS, some sympathetic neurons                                               2-MeSATP ⩾ ATP ⩾ Ap~4~A ⩾ α,β-meATP (rapid desensitisation); PAPET-ATP; BzATP                                                       TNP-ATP, AF353, A317491, RO3, isoPPADS \> NF110 \> PPADS, Ip~5~I, phenol red, RN-1838, Spinorphin                                                                                                                      Intrinsic cation channel

             P2X4                CNS, testis, colon, endothelial cells, microglia                                              ATP \>\> α,β-meATP \>\> CTP, 2-MeSATP Ivermectin potentiation                                                                       5-BDBD \>\> TNP-ATP, PPADS \> BBG, Paroxetine, phenolphthalein, CO donor (CORM 2), 5MPTP                                                                                                                               Intrinsic ion channel (especially Ca^2+^)

             P2X5                Proliferating cells in skin, gut, bladder, thymus, spinal cord, heart, adrenal medulla        ATP = 2-MeSATP = ATPγS \>\> α,β-meATP \> AP~4~A                                                                                     BBG \> PPADS, Suramin                                                                                                                                                                                                  Intrinsic ion channel

             P2X6                CNS, motor neurons in spinal cord                                                             Only functions as a heteromultimer                                                                                                  --                                                                                                                                                                                                                     Intrinsic ion channel

             P2X7                Immune cells including dendritic cells (mast cells, macrophages), pancreas, skin, microglia   BzATP \> ATP ⩾ 2-MeSATP \>\> α,β-meATP (clemastine potentiates)                                                                     KN62, BBG, KN04, MRS2427, O-ATP, RN-6189, Perazine, AZ10606120, A740003, A-438079, A-804598, GSK-1370319, Comp 31 (GSK), AZD-9056, CE-224,535, JNJ-47965567, JNJ-42253432 (penetrates BBB), decavanadate, AZ11657312   Intrinsic cation channel and a large pore with prolonged activation

  P2Y        P2Y~1~              Epithelial and endothelial cells, platelets, immune cells, osteoclasts, brain                 MRS2365 \> 2-MeSADP = Ap~5~(γB) \>\> ADPβS \> ATP \> 2-MeSATP = ADP                                                                 MRS2500 \> MRS2279 \> MRS2179, PIT, A3P5P                                                                                                                                                                              G~q~/G~11~; PLC-β activation

             P2Y~2~              Immune cells, epithelial and endothelial cells, kidney tubules, osteoblasts                   2-thio-UTP \> UTP, MRS2698 ⩾ ATP, INS 365 \> INS 37217, UTPγS \> Ap~4~A \> MRS 2768, Up~4~-phenyl ester                             AR-C126313 \> Suramin \> RB2, PSB-716, MRS2576, PSB-0402, AR-C118925                                                                                                                                                   G~q~/G~11~ and possibly G~i~/G~o~; PLC-β activation

             P2Y~4~              Endothelial cells, placenta, spleen, thymus                                                   2′-azido-dUTP \> UTPγS, UTP ⩾ ATP ⩾ Ap~4~A Up~4~U MRS4062                                                                           ATP (human) \> Reactive Blue 2 \> Suramin, MRS2577, PPADS                                                                                                                                                              G~q~/G~11~ and possibly G~i~; PLC-β activation

             P2Y~6~              Airway and intestinal epithelial cells, placenta, T cells, thymus, microglia (activated)      MRS2693 \> UDPβS, PSB0474 \> INS48823, Up~3~U, 3-phenacyl-UDP \>\> UDP \> UTP \>\> ATP, α,β-meUDP, MRS2957, MRS4129, 5-OMe-UDP αB   MRS2578 \> Reactive Blue 2, PPADS, MRS2567, MRS2575 (human)                                                                                                                                                            G~q~/G~11~; PLC-β activation

             P2Y~11~             Spleen, intestine, granulocytes                                                               ATPγS \> AR-C67085MX \> BzATP ⩾ ATP, NF546, NAD^+^, NAADP^+^, S*p*-2-propylthio-ATP-α-B                                             NF157 \> Suramin \> RB2, 5′-AMPS, NF340, AMP-α-5                                                                                                                                                                       G~q~/G~11~ and G~S~; PLC-β activation

             P2Y~12~             Platelets, glial cells                                                                        2-MeSADP ⩾ ADP \> ATP, ADP-β-S                                                                                                      AR-C69931MX \> AZD6140 (Ticagrelor), INS50589 \> RB2 \> 2-MeSAMP AR-C66096, CT50547, PSB-0413, Carba-nucleosides, MRS2395, AR-C67085, \[^3^H\]PSB-0413; clopidogrel, AZD1283; ACT-246475                               Gα~I~; inhibition of adenylate cyclase

             P2Y~13~             Spleen, brain, lymph nodes, bone marrow, erythrocytes                                         ADP = 2-MeSADP \> 2-MeSATP, ATP                                                                                                     AR-C69931MX \> AR-C67085 \> MRS2211, 2-MeSAMP                                                                                                                                                                          G~i~/G~o~

             P2Y~14~\            Placenta, adipose tissue, stomach, intestine, discrete brain regions, mast cells\             MRS2690 \> UDP \> UDP glucose ⩾ UDP-galactose, UDP-glucosamine, MRS2905\                                                            PPTN\                                                                                                                                                                                                                  G~q~/G~11~\
             GPR17               Oligodendrocytes                                                                              Uracil nucleotides/cysteinyl-leukotrienes, MDL29,951                                                                                PZB01415033                                                                                                                                                                                                            G~i~, adenylate cyclase inhibition
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Source: Updated from [@bibr26-2398212818817494], with permission from Elsevier.

A3P5P: adenosine-3′-5′-bisphosphate; ADP: adenosine 5′-diphosphte; ADPβS: adenosine-5′-(β-thio)-diphosphate; 5′-AMPS: 5′-O-thiomnophosphate; Ap~4~A: diadenosine tetraphosphate; Ap5(γβ): adenosine pentaphosphate (βγ); ATPγS: adenosine-5′-(γ-thio)-triphosphate; ATP: adenosine 5′-triphosphte; ATPγS: adenosine-5′-(γ-thio)-triphosphate; BBG: brilliant blue green; 5-BDBD: 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro\[3,2-e\]-1,4-diazepin-2-one; BzATP: 2′(3′)-O-(4-benzoylbenzoyl) adenosine 5′-triphosphate; β,γ-CF2ATP: α,β-difluoromethylene-ATP; cAMP: cyclic AMP; CCPA: chlorocyclopentyl adenosine; 2-Cl-IB-MECA: 2-chloro-N6-(3-iodobenzyl)-9-\[5-(methylcarbamoyl)-β-[d]{.smallcaps}-ribofuranosyl\]adenine; CNS: central nervous system; CORM 2: carbon monoxide donor 2; CTP: cytosine triphosphate; DBXRM: 1,3-dibutylxanthine 7-riboside 5′-*N*-methylcarboxamide; DPCPX: 1,3-dipropyl-8-cyclopentylxanthine; GTP: guanosine-5′-triphosphate; HEMADO: 2-(1-Hexynyl)-*N*-methyl adenosine; HENECA: 2-hexynyladenosine-59-N-ethylcarboxamide; IB-MECA: N6-(3-Iodobenzyl)-9-\[5-(methylcarbamoyl)-β-[d]{.smallcaps}-ribofuranosyl\]adenine; IP~5~I: di-inosine pentaphosphate; isoPPADS: iso-pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; L-α,β-meATP: L-α,β-methylene ATP; L-β,γ-meATP: L-β,γ-methylene ATP; 2′-MeCCPA: 2-chloro-*N*-cyclopentyl-2′-methyladenosine; 2-MeSADP: 2-methylthio ADP; 2-MeSAMP: 2-methylthio AMP; 2-MeSATP: 2-methylthio ATP; α,β-meUDP: α,β-methylene UDP; NAADP^+^: nicotinic acid adenine dinucleotide phosphate; NAD^+^: nicotinamide adenine dinucleotide; NECA: 5′-*N*-ethylcarboxamido adenosine; NTS: nucleus tractus solitarius; oATP: oxidised ATP; PAPET: 2-\[2-(4-aminophenyl)ethylthio\]adenosine-5′-triphosphate; PIT: 2,2′-pyridylisatogen tosylate; PLC: phospholipase C; PPADS: pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid; RB2: reactive blue 2; R-PIA: R-phenylisopropyladenosine; S(--)-ENBA: (2S)-N6-\[2-endo-Norbornyl\]adenosine; 2-thio-UTP: 2-thio-uridine 5′-triphosphate; TNP-ATP: 2′(3′)-O-(2,4,6-trinitrophenyl) ATP; UDP: uridine 5′-diphosphate; UDPβS: uridine 5′-O-thiodiphosphate; Up~3~U: diuridine triphosphate; Up4-phenyl ester: uridine tetraphosphate phenyl ester; Up~4~U: diuridine tetraphosphate; UTP: uridine 5′-triphosphate; UTPγS: uridine 5′-O-3-thiotriphosphate.

P2X receptor subtype agonist potencies are based on rat preparations, while P1 and P2Y receptor subtype agonist potencies are based on human preparations (=, equal potency; \>, greater potency; ⩾, greater than or equal potency).

P2X receptors {#section3-2398212818817494}
=============

P2X1-7 receptors show a subunit topology of intracellular N- and C- termini possessing consensus binding motifs for protein kinases and two transmembrane-spanning regions (TM1 and TM2). TM1 is involved with channel gating and TM2 lining the ion pore. There is a large extracellular loop, with 10 conserved cysteine residues (see [@bibr5-2398212818817494]; [@bibr88-2398212818817494]; [@bibr95-2398212818817494]). The stoichiometry of P2X1-7 receptors involves three subunits, which form a stretched trimer or a hexamer of conjoined trimers ([@bibr86-2398212818817494]; [@bibr88-2398212818817494]; [@bibr107-2398212818817494]). Heteromultimers as well as homomultimers are involved in forming the trimer ion pore ([@bibr86-2398212818817494]), including P2X2/3, P2X1/2, P2X1/5, P2X2/6, P2X4/6 and P2X1/4 receptors. Advances have been made by the use of knockout mice for P2X1, P2X2, P2X3, P2X4 and P2X7 receptors and transgenic mice that overexpress the P2X1 receptor. The association of various diseases with P2X receptor polymorphisms has been described (see [@bibr46-2398212818817494]).

P2X receptor subtypes {#section4-2398212818817494}
=====================

A complementary DNA (cDNA) encoding the P2X1 receptor was made from rat vas deferens ([@bibr116-2398212818817494]). The agonist actions of ATP by α,β-methylene ATP (α,β-meATP) distinguish P2X1 and P2X3 receptors from the other homomeric forms. Several antagonists have been recognised to be selective for P2X1 receptors (see [Table 1](#table1-2398212818817494){ref-type="table"}). Adenoviral expression of a P2X1 receptor-green fluorescent protein construct shows the receptor to be localised in clusters in vas deferens, with larger clusters apposing nerve varicosities ([@bibr28-2398212818817494]).

Rat P2X2 receptor cDNA was isolated from PC12 cells ([@bibr15-2398212818817494]) and human receptor cDNA from pituitary gland ([@bibr84-2398212818817494]). No agonists are currently known at present that are selective for P2X2 receptors. However, protons and low concentrations of zinc and copper potentiate P2X2 receptors. Antagonists for P2X2 receptors are shown in [Table 1](#table1-2398212818817494){ref-type="table"}. The P2X2 receptor is non-desensitising, compared with the P2X1 and P2X3 receptors.

P2X1/2 heteromultimer receptors have been described in de-folliculated *Xenopus* oocytes ([@bibr17-2398212818817494]; [@bibr44-2398212818817494]). pH sensitivity is characteristic of heteromeric P2X1/2 ion channels.

P2X3 receptor subunit cDNAs were taken from rat dorsal root ganglion cDNA libraries ([@bibr48-2398212818817494]; [@bibr80-2398212818817494]), from a human heart cDNA library ([@bibr62-2398212818817494]) and a zebrafish library ([@bibr57-2398212818817494]). The antagonist NF023 is about 20 times less effective at P2X3 compared to P2X1 receptors (see [Table 1](#table1-2398212818817494){ref-type="table"}). P2X3 receptors are prominently expressed on sensory neurons, including nociceptive nerve endings ([@bibr26-2398212818817494]).

P2X2/3 heteromer receptors have been described ([@bibr80-2398212818817494]; [@bibr104-2398212818817494]). They exhibit a sustained current elicited by α,β-meATP. However, like homomeric P2X2 receptors, they are potentiated by low pH and, in common with the homomeric P2X3 receptor, they are very sensitive to block by 2′(3′)-O-(2,4,6-trinitrophenyl) ATP. P2X2/3 receptors are expressed by subpopulations of sensory neurons, sympathetic ganglion cells and brain neurons.

cDNAs for rat P2X4 receptors were isolated from both superior cervical ganglion (SCG) and brain ([@bibr9-2398212818817494]; [@bibr18-2398212818817494]). cDNAs for human, mouse, chick and *Xenopus* have also been isolated. P2X4 receptors are activated by ATP, but not by α,β-meATP. A useful distinguishing feature of ATP-evoked currents at P2X4 receptors is their potentiation by ivermectin. Unusual among the P2X receptors, the rat P2X4 receptor shows relative insensitivity to blockade by the conventional non-selective antagonists suramin and pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS). Carbamazepine derivatives have been claimed to be potent P2X4 receptor antagonists ([@bibr113-2398212818817494]; see [Table 1](#table1-2398212818817494){ref-type="table"}). Currents evoked by ATP at the mouse P2X4 receptor are increased by PPADS and suramin, probably because they are also ectonucleotidase inhibitors ([@bibr26-2398212818817494]).

P2X1/4 heteromeric receptors were shown to have kinetic properties resembling homomeric P2X4 receptors and a pharmacological profile similar to homomeric P2X1 receptors ([@bibr87-2398212818817494]). An important advance was made when the crystal structure of the P2X4 receptor was described ([@bibr69-2398212818817494]; [Figure 1](#fig1-2398212818817494){ref-type="fig"}).

![The architecture of the P2X4 receptor. Stereoview of the homotrimeric ΔzfP2X4 structure viewed parallel to the membrane. Each subunit is depicted in a different colour. *N*-acetylglucosamine (NAG) and glycosylated asparagine residues are shown in stick representation. The grey bars suggest the boundaries of the outer (out) and inner (in) leaflets of the membrane bilayer.\
Source: Reproduced from [@bibr69-2398212818817494], with permission from the Nature Publishing Group.](10.1177_2398212818817494-fig1){#fig1-2398212818817494}

P2X5 receptor cDNA was first isolated from rat coeliac ganglion and heart ([@bibr26-2398212818817494]; [@bibr61-2398212818817494]). It was also cloned from embryonic chick skeletal muscle ([@bibr8-2398212818817494]) and a bullfrog P2X5 receptor from larval skin. Human P2X5 receptor cDNAs are missing exon 10 (hP2X~5a~) or exons 3 and 10 (P2X~5b~) ([@bibr94-2398212818817494]; [@bibr108-2398212818817494]). Currents elicited by ATP in cells expressing the rat P2X5 receptor are of small amplitude, compared with the currents observed with P2X1, P2X2, P2X3 or P2X4 receptors. P2X5 mRNA is highly expressed in developing skeletal muscle ([@bibr26-2398212818817494]).

The P2X1/5 heteromer is characterised by a sustained current evoked by α,β-meATP, which does not occur for either of the homomers when expressed separately ([@bibr28-2398212818817494]; [@bibr111-2398212818817494]). Cells expressing P2X1/5 receptors are more sensitive to ATP than those with homomeric receptors. P2X2/5 heteromeric receptors have also been recognised ([@bibr53-2398212818817494]).

The rat P2X6 receptor was cloned from SCG ([@bibr28-2398212818817494]) and rat brain ([@bibr103-2398212818817494]). The human equivalent was isolated from peripheral lymphocytes and was abundantly expressed in human and mouse skeletal muscle. The P2X6 subunit is only functionally expressed as a heteromultimer.

Heteromeric P2X2/6 receptors were expressed in HEK293 cells ([@bibr114-2398212818817494]). The most convincing difference in oocytes expressing P2X2/6 receptors compared to those expressing only P2X2 receptors is that at pH 6.5 the inhibition of the current by suramin is biphasic ([@bibr72-2398212818817494]). P2X2/6 receptors are expressed particularly by respiratory neurons in the brain stem.

P2X4/6 heteromeric receptors were described in oocytes ([@bibr71-2398212818817494]). The P2X4/6 heteromer differs only in minor respects from that of P2X4 homomers. They are prominently expressed in adult trigeminal mesencephalic nucleus and in hippocampal CA1 neurons ([@bibr88-2398212818817494]).

A chimeric cDNA encoding the rat P2X7 receptor was first isolated from SCG and medial habenula. Full-length cDNAs were later isolated from a rat brain cDNA library ([@bibr110-2398212818817494]). The unique feature of the P2X7 receptor is that in addition to the usual rapid opening of the cation-selective ion channel, with prolonged exposure to high concentrations of ATP it undergoes a channel to pore conversion to allow the passage of large dye molecules such as ethidium and YO-PRO-1. This often leads to apoptotic cell death. 2′,3′-O-(benzoyl-4-benzoyl)-ATP (BzATP) is a potent, although not selective, agonist at the P2X7 receptor. After continuous application of BzATP (30 µM) for about 30 s, the plasma membrane develops large blebs. Blebs are usually preceded by the shedding of smaller vesicles (\<1 µm diameter) that release inflammatory cytokines. A number of potent antagonists have been developed (see [Table 1](#table1-2398212818817494){ref-type="table"}).

P2Y receptors {#section5-2398212818817494}
=============

P2Y~1~ and P2Y~2~ receptors were cloned in 1993 ([@bibr83-2398212818817494]; [@bibr122-2398212818817494]). Since then several other subtypes have been isolated by homology cloning. The G~i~-coupled ADP receptor (P2Y~12~) of platelets was isolated by expression cloning in 2001 ([@bibr66-2398212818817494]). P2Y~13~ and P2Y~14~ receptors were characterised during a study of orphan receptors ([@bibr47-2398212818817494]; [@bibr50-2398212818817494]). At present, there are eight recognised human P2Y receptors: P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, P2Y~11~, P2Y~12~, P2Y~13~ and P2Y~14~ ([@bibr3-2398212818817494], [@bibr4-2398212818817494]; see [Table 1](#table1-2398212818817494){ref-type="table"}). The missing numbers represent either non-mammalian orthologs or receptors which have no functional evidence of responsiveness to nucleotides. A p2y8 receptor was cloned from the frog embryo, which was shown to be involved in the development of the neural plate ([@bibr11-2398212818817494]). A P2Y-like receptor, GPR17, has been described ([@bibr90-2398212818817494]). Two distinct P2Y receptor subgroups characterised by a relatively high level of sequence divergence have been identified ([@bibr4-2398212818817494]). The first subgroup includes P2Y~1,2,4,6,11~ and the second subgroup includes the P2Y~12,13,14~ subtypes (see [Figure 2](#fig2-2398212818817494){ref-type="fig"}). For some of the P2Y receptor subtypes, potent and selective synthetic agonists and antagonists have been identified (see [Table 1](#table1-2398212818817494){ref-type="table"}). Activation of several P2Y receptors is associated with the stimulation of mitogen-activated protein kinase (MAPK; [@bibr4-2398212818817494]). Ion channel couplings of P2Y receptors are primarily of importance in neurons, but they have been detected in various other tissues, including cardiac muscle cells ([@bibr4-2398212818817494]; [@bibr118-2398212818817494]). Polymorphisms of P2Y~1~, P2Y~2~ and P2Y~12~ receptors have been identified associated with various diseases ([@bibr74-2398212818817494]; [@bibr79-2398212818817494]; [@bibr123-2398212818817494]). There is dimerisation involving P2Y receptors with non-P2Y receptors, for example, rat P2Y~1~ and adenosine A~1~ receptors in neurons, in rat cortex, hippocampus and cerebellum ([@bibr128-2398212818817494]). Functional P2Y~1~ and P2Y~2~ receptors, co-localised at the neuromuscular junctions with nicotinic acetylcholine (ACh) receptors, have been reported in mammalian, chicken and amphibian muscles.

![(a) Dendrogram to show relatedness of 29 P2X receptor subunits. Full-length amino acid sequences were aligned with Clustal W using default parameters. The dendrogram was constructed with TreeView. h, human (*Homo sapiens*); r, rat (*Rattus norvegicus*); m, mouse (*Mus musculus*); gp, guinea pig (*Cavia porcellus*); c, chicken (*Gallus gallus*); zf, zebrafish (*Danio rerio*); bf, bullfrog (*Rana catesbeiana*); x, claw-toed frog (*Xenopus laevis*); f, fugu (*Takifugu rubripes*). The ellipses indicate the apparent clustering by relatedness into subfamilies. Source: Reproduced from [@bibr88-2398212818817494], with permission from the American Physiological Society. (b) A phylogenetic tree (dendrogram) showing the relationships among the current members of the P2Y receptor family (human P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, P2Y~11~, P2Y~12~ and P2Y~13~ receptors) and the human UDP-glucose receptor (here indicated as the P2Y~14~ receptor). The P2Y receptors can be divided into two subgroups shown with green and lilac backgrounds. Sequences were aligned using CLUSTALX and the tree was built using the TREEVIEW software. Source: Reproduced from [@bibr3-2398212818817494], with permission from Elsevier.](10.1177_2398212818817494-fig2){#fig2-2398212818817494}

P2Y receptor subtypes {#section6-2398212818817494}
=====================

P2Y~1~ receptors have been cloned and characterised in human, rat, mouse, cow, chick, turkey and *Xenopus* tissues. ADP is a more potent agonist than ATP and 2-methylthio ADP is even more potent. The most effective antagonists to display selectivity for the P2Y~1~ receptor at present are MRS2179, MRS2279 and MRS2500 (see [Table 1](#table1-2398212818817494){ref-type="table"}). P2Y~1~ mRNA is high in different regions of the human brain, prostate gland and placenta ([@bibr39-2398212818817494]; [@bibr78-2398212818817494]). In post-mortem brain sections from Alzheimer's disease patients, the P2Y~1~-like immunoreactivity in the hippocampus and entorhinal cortex was localised to neurofibrillary tangles, neuritic plaques and neuropil threads ([@bibr85-2398212818817494]).

P2Y~2~ receptors have been cloned and characterised from human, rat, mouse, canine and porcine cells or tissues ([@bibr102-2398212818817494]). P2Y~2~ receptors are activated by equivalent concentrations of ATP and UTP. The γ-thiophosphate, UTPγS and INS 37217 are potent hydrolysis-resistant agonists of P2Y~2~ receptors ([@bibr4-2398212818817494]). Current P2Y~2~ receptor antagonists are shown in [Table 1](#table1-2398212818817494){ref-type="table"}. Expression of P2Y~2~ receptor mRNA has been described in many tissues ([@bibr39-2398212818817494]). P2Y~2~ receptor expression in smooth muscle cells is up-regulated by inflammatory agents, including interleukin-1β, interferon-γ and tumour necrosis factor-α ([@bibr67-2398212818817494]). In epithelial cells, P2Y~2~ receptor activation increases Cl^−^ secretion and inhibits Na^+^ absorption ([@bibr70-2398212818817494]). A P2Y~2~ receptor knockout mouse has been described that is defective in nucleotide-stimulated ion secretion in airway epithelial cells ([@bibr54-2398212818817494]). P2Y~2~ receptors inhibit bone formation by osteoblasts ([@bibr65-2398212818817494]) and N-type calcium currents in neurons ([@bibr16-2398212818817494]).

P2Y~4~ receptors have been cloned and characterised from human, rat and mouse. UTP is the most potent activator of the human P2Y~4~ receptor ([@bibr51-2398212818817494]). However, the recombinant rat and mouse P2Y~4~ receptors are activated equipotently by ATP and UTP ([@bibr12-2398212818817494]). Reactive Blue 2 blocks rat P2Y~4~ receptors, but only partially blocks human P2Y~4~ receptors. P2Y~4~ mRNA and protein was most abundant in the intestine of both mouse and humans, but has also been described in other organs ([@bibr39-2398212818817494]). P2Y~4~-null mice show normal behaviour, growth and reproduction; however, the chloride secretory response to apical UTP and ATP of the jejunal epithelium was abolished ([@bibr93-2398212818817494]).

P2Y~6~ receptors are selective for UDP in mouse, rat and human ([@bibr75-2398212818817494]). Selective agonists and antagonists are described in [Table 1](#table1-2398212818817494){ref-type="table"}. A wide tissue distribution of P2Y~6~ mRNA and protein has been reported, and the highest expression was in spleen, intestine, liver, brain and pituitary ([@bibr39-2398212818817494]).

The human P2Y~11~ receptor has a unique profile ([@bibr4-2398212818817494]). The hP2Y~11~ receptor gene differs from other P2Y receptor subtype genes having the presence of a 1.9-kb intron in the coding sequence that separates an exon encoding the first 6 amino acid residues from a second exon encoding the remaining part of the protein ([@bibr52-2398212818817494]).

P2Y~12~ receptors have been identified and characterised in human, rat and mouse ([@bibr4-2398212818817494]). ADP is the agonist of this receptor. The P2Y~12~ receptor is highly expressed in platelets where it is the molecular target of antiplatelet drugs, clopidogrel and ticagrelor ([@bibr98-2398212818817494]). The P2Y~12~ receptor is also expressed in sub-regions of the brain, glial cells, brain capillary endothelial cells, smooth muscle cells and chromaffin cells ([@bibr39-2398212818817494]). P2Y~13~ receptors have been identified and characterised in human, mouse and rat ([@bibr4-2398212818817494]). Naturally occurring agonists of the P2Y~13~ receptor are ADP and di-adenosine triphosphate. Selective antagonists of the human P2Y~13~ receptor are shown in [Table 1](#table1-2398212818817494){ref-type="table"}. The P2Y~13~ receptor is expressed in spleen, placenta, liver, heart, bone marrow, monocytes, T cells, lung and various regions of the brain ([@bibr60-2398212818817494]).

The P2Y~14~ receptor is 47% identical to the P2Y~12~ and P2Y~13~ receptors. The gene for this receptor is in human chromosome 3q24-3q25 ([@bibr3-2398212818817494]). The P2Y~14~ receptor is activated by UDP-glucose and is coupled to the G~i/o~ family of G proteins ([@bibr64-2398212818817494]). P2Y~14~ mRNA is distributed in many systems in the human body. Chemoattractant and neuroimmune functions have been claimed for the P2Y~14~ receptor.

Physiology of purinergic signalling {#section7-2398212818817494}
===================================

Early studies were focused largely on short-term purinergic signalling in neurotransmission, neuromodulation, secretion, chemoattraction and acute inflammation, but there is increasing interest in long-term (trophic) signalling involving cell proliferation, differentiation, motility and death in development, regeneration, wound healing, restenosis, epithelial cell turnover, cancer and ageing ([@bibr2-2398212818817494]; [@bibr41-2398212818817494]). In blood vessels, there is dual purinergic short-term control of vascular tone by ATP ([@bibr25-2398212818817494]): ATP released as a cotransmitter from perivascular sympathetic nerves activate P2X receptors resulting in contraction of smooth muscle; ATP released from endothelial cells during changes in blood flow (shear stress) and hypoxia acts on P2X and P2Y receptors on endothelial cells, resulting in production of nitric oxide and relaxation. There is also long-term control of cell proliferation and differentiation, migration and death involved neovascularisation, restenosis following angioplasty and atherosclerosis ([@bibr58-2398212818817494]). Purinergic signalling is involved in development, ageing and regeneration ([@bibr28-2398212818817494]). Purinergic receptors are expressed on stem cells ([@bibr40-2398212818817494]; [@bibr55-2398212818817494]; [@bibr115-2398212818817494]). Many cell types release ATP physiologically in response to gentle mechanical distortion, hypoxia or some agents ([@bibr10-2398212818817494]). The mechanism of ATP transport includes, in addition to vesicular release, ABC transporters, connexin or pannexin hemi-channels, maxi-ion channels and even P2X7 receptors ([@bibr28-2398212818817494]; [@bibr76-2398212818817494]). Extracellular breakdown of released ATP is by ectonucleotidases, including E-NTPDases, E-NPPS, alkaline phosphatase and ecto-5′-nucleotidose ([@bibr127-2398212818817494]; [@bibr130-2398212818817494]). P1 and P2 receptors are involved in neurotransmission and neuromodulation in the CNS, and in normal behaviour, including memory, feeding, locomotion and cognition ([@bibr43-2398212818817494]).

Purinergic pathophysiology and therapeutic potential {#section8-2398212818817494}
====================================================

ATP was shown early to be a major cotransmitter with ACh in parasympathetic nerves mediating contraction of the urinary bladder of rodents ([@bibr42-2398212818817494]). However, in healthy human bladder, the role of ATP as a cotransmitter is minor, but under pathological conditions, such as interstitial cystitis, outflow obstruction and most types of neurogenic bladder, the purinergic component is increased to about 40% ([@bibr24-2398212818817494], [@bibr27-2398212818817494]). There is also a significantly greater cotransmitter role for ATP in sympathetic nerves in spontaneously hypertensive rats ([@bibr120-2398212818817494]). P2X3 receptors are located on small nociceptive sensory nerves and are involved in the initiation of pain ([@bibr14-2398212818817494]; [@bibr22-2398212818817494], [@bibr34-2398212818817494]; [@bibr48-2398212818817494]). There are peripheral extensions of the sensory nerves in skin, tongue and visceral organs and central projections to inner lamina 2 of the spinal cord. A hypothesis describing purinergic mechanosensory transduction and pain in visceral organs was published in 1999 ([@bibr23-2398212818817494]). It was proposed that ATP, released from urothelial/epithelial cells during distension, acts on P2X3 and P2X2/3 receptors on subepithelial sensory nerve endings to send nociceptive messages via sensory ganglia to the pain centres in the brain ([@bibr23-2398212818817494]). Supporting evidence has been reported in the bladder ([@bibr121-2398212818817494]), ureter ([@bibr96-2398212818817494]) and gut ([@bibr126-2398212818817494]). Purinergic mechanosensory transduction via low threshold fibres is also involved in urine voiding ([@bibr49-2398212818817494]). Antagonist to P2X4, P2X7 and P2Y~12~ receptors on microglia have been shown to reduce neuropathic and inflammatory pain ([@bibr31-2398212818817494]; [@bibr68-2398212818817494]). There is increasing attention to the potential roles of purinergic signalling in trauma, ischaemia and neurodegenerative conditions, including Alzheimer's, Parkinson's and Huntington's diseases, multiple sclerosis and amyotrophic lateral sclerosis ([@bibr28-2398212818817494]; [@bibr105-2398212818817494]). The involvement of purinergic signalling in epilepsy, neuropsychiatric diseases and mood disorders has also been reported ([@bibr13-2398212818817494]; [@bibr30-2398212818817494]).

Purinergic agents are being investigated for the treatment of disorders of the urinary tract ([@bibr32-2398212818817494]), skeletal muscle ([@bibr97-2398212818817494]), gut ([@bibr29-2398212818817494]), bone ([@bibr36-2398212818817494]; [@bibr89-2398212818817494]), the cardiovascular system ([@bibr58-2398212818817494]), kidney ([@bibr6-2398212818817494]; [@bibr112-2398212818817494]) and the reproductive system ([@bibr45-2398212818817494]; [@bibr63-2398212818817494]). There are also reports that extracellular ATP acts on P2Y~2~ receptors to facilitate HIV-1 infection (e.g. [@bibr99-2398212818817494]). The therapeutic potential of purinergic compounds for the treatment of cancer is being explored ([@bibr37-2398212818817494]; [@bibr100-2398212818817494]; [@bibr101-2398212818817494]; [@bibr106-2398212818817494]; [@bibr124-2398212818817494]; [@bibr125-2398212818817494]). Selective purinoceptor agonists and antagonists with therapeutic potential are also being developed for thrombosis and stroke, atherosclerosis, kidney failure, osteoporosis, bladder incontinence and colitis ([@bibr7-2398212818817494]; [@bibr27-2398212818817494], [@bibr34-2398212818817494]). This would be facilitated by the discovery of selective purinoceptor agonists and antagonists that are orally bioavailable and stable in vivo.
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